CYP3A4*22: Promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy
Pharmacogenomics , Volume 14 - Issue 1 p. 47- 62
Many studies have attempted to explain the interindividual variability observed in drug metabolism by assessing the impact of SNPs in genes implicated in drug absorption, distribution, metabolism and excretion pathways. Particular attention has been paid to the CYP450s. CYP3A4 is the main CYP isoform in human liver and intestine and is involved in the metabolism of many drugs. Its activity, however, is characterized by widespread variation in the general population, which is thought to have a genetic basis. A new CYP3A4 allele (CYP3A4*22; rs35599367 C>T in intron 6) with a frequency of 5-7% in the Caucasian population was recently discovered through its association with low hepatic CYP3A4 expression and CYP3A4 activity, and showing effects on statin, tacrolimus and cyclosporine metabolism. This review will summarize the current literature on phenotypes linked to this new promising CYP3A4 genetic marker SNP and discusses the potential clinical relevance.
|CYP3A4, CYP3A4*22, personalized medicine, pharmacogenetics, rs35599367, single nucleotide polymorphisms, statins, tacrolimus|
|Organisation||Department of Clinical Chemistry|
Elens, L, van Gelder, T, Hesselink, D.A, Haufroid, V, & van Schaik, R.H.N. (2013). CYP3A4*22: Promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics (Vol. 14, pp. 47–62). doi:10.2217/pgs.12.187